Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Galmed Pharmaceuticals Ltd. (EOCN) had Stock-Based Compensation of $0.16M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-1.91M |
|
-- |
|
-- |
|
$2.04M |
|
$-2.04M |
|
$0.13M |
|
$-1.91M |
|
$-1.91M |
|
$-1.91M |
|
$-1.91M |
|
$-1.91M |
|
$-1.91M |
|
$-2.04M |
|
$-2.04M |
|
0.82M |
|
0.82M |
|
$-2.32 |
|
$-2.32 |
|
| Balance Sheet Financials | |
$16.03M |
|
-- |
|
-- |
|
$16.03M |
|
$2.08M |
|
-- |
|
-- |
|
$2.08M |
|
$13.95M |
|
$13.95M |
|
$13.95M |
|
0.82M |
|
| Cash Flow Statement Financials | |
$-2.54M |
|
$0.15M |
|
-- |
|
$4.11M |
|
$1.73M |
|
$-2.38M |
|
|
Stock-Based Compensation |
$0.16M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.71 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.54M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.69% |
|
-13.69% |
|
-11.92% |
|
-13.69% |
|
$16.91 |
|
$-3.08 |
|
$-3.08 |
|